Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of BL0020 in Advanced Solid Tumors
NCT05886868Phase 1Recruiting
- Sponsor
- Shanghai Best-Link Bioscience
- Start
- Oct 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of BL0020 in solid tumor, triple-negative breast cancer (TNBC), small cell lung cancer (SCLC) and 1 more, sponsored by Shanghai Best-Link Bioscience. Primary endpoints: Maximum Tolerated Dose at 2 years and Recommended Phase II Dose at 2 years. Started Oct 2023; status: recruiting.
02
Drugs
BL0020
03
Conditions
solid tumortriple-negative breast cancer (TNBC)small cell lung cancer (SCLC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05886868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05886868.